Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ PASC 40% Improvement Relative Risk HCQ  COVAD  Prophylaxis  LONG COVID Does HCQ reduce the risk of Long COVID (PASC)? Retrospective study in multiple countries (January - May 2022) Lower PASC with HCQ (not stat. sig., p=0.079) c19hcq.org Sen et al., The Lancet Rheumatology, Apr 2023 Favors HCQ Favors control

Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study

Sen et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(23)00066-8, COVAD
Apr 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Retrospective 755 autoimmune rheumatic disease patients, showing lower risk of PASC (long COVID) with HCQ use, without statistical significance.
risk of PASC, 40.0% lower, OR 0.60, p = 0.08, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sen et al., 24 Apr 2023, retrospective, multiple countries, peer-reviewed, survey, 8 authors, study period 31 January, 2022 - 21 May, 2022, COVAD trial. Contact: drlatikagupta@gmail.com.
This PaperHCQAll
Abstract: Comment Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study As COVID-19 gradually becomes endemic in many parts of the world, a silent epidemic of post-COVID-19 condition is emerging. Post-COVID-19 condition comprises a constellation of long-term sequelae defined as the persistence or new appearance of symptoms 3 months after a SARS-CoV-2 infection.1 Patients with autoimmune rheumatic diseases and other autoimmune diseases are at increased risk for developing severe COVID-19,2 and might also be at higher risk of developing more severe long-term COVID-19 sequelae compared with the general population.3 However, post-COVID-19 condition is poorly understood in these patients, and the knowledge of specific risk factors for post-COVID-19 condition and of its effects on mental and physical function is scarce and remains an unmet need. With data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) international, multicentre electronic patient survey, which involved 157 collaborators from 106 countries,4 we analysed the prevalence and predictors of post-COVID-19 condition, the association between the condition and disease flares, and its on physical and mental function in patients with rheumatic and non-rheumatic autoimmune diseases compared with healthy controls. We circulated a validated patient questionnaire via collaborating centres, patient support groups, and social media platforms to collect data on demographics, type of autoimmune disease, treatment history, comorbidities, SARS-CoV-2 infection history and COVID-19 disease course, COVID-19 vaccination history, disease flares, current symptom status, and patient reported outcomes (including fatigue visual analogue scale, pain visual analogue scale, PROMIS10a global mental and physical function, and quality of life; appendix pp 1–2). Post-COVID-19 condition was defined as the persistence of any symptom beyond 3 months after SARS-CoV-2 infection, per the WHO definition. Participants provided informed consent to participate and ethical approval was obtained from the Institutional Ethics Committee of the Sanjay Gandhi Postgraduate Institute of Medical Sciences (Lucknow, India). www.thelancet.com/rheumatology Vol 5 May 2023 Questionnaires were submitted by 12 358 individuals between Jan 31 and May 21, 2022. Questionnaires with incomplete entries (4692 [38·0%]) were excluded. Of the 7666 (62·0%) individuals who submitted complete questionnaires, 2640 (34·4%) reported having a positive SARS-CoV-2 test. 1677 (63·5%) of these 2640 respondents completed the survey more Univariate OR (95% CI) See Online for appendix Multivariable* p value OR (95% CI) p value Demographics Age ·· 0·013 1·0 (0·9–1·0) 0·48 Female sex 2·0 (0·9–4·4) 0·050 2·1 (0·8–4·9) 0·089 Country by HDI ·· 0·051 0·8 (0·7–1·1) 0·20 White 1·7 (1·1–2·8) 0·018 1·3 (0·6–2·4) 0·41 Mixed ethnicity 0·9 (0·9–0·9) 0·028 ·· 0·99 Asian ethnicity 0·5 (0·2–1·4) 0·26 ·· ·· Hispanic ethnicity 0·9 (0·5–1·9) 0·99 ·· ·· African American ethnicity 0·9 (0·3–2·0) 0·80 ·· ·· Disease duration ·· 0·43 ·· ·· Any comorbidities 3·3 (1·90–5·5) <0·0001 2·0 (1·1–3·6) 0·026 AID comorbidity 2·3 (1·4–3·9) 0·0006 1·4 (0·7–2·5) 0·25 Asthma 2·6 (1·5–4·7) <0·0001 1·3 (0·6–2·6) 0·41 Chronic kidney disease 2·0 (0·8–4·7) 0·10 ·· ·· Chronic liver disease† 11·6 (2·5–52·8) <0·0001 ·· ·· Chronic obstructive..
{ 'DOI': '10.1016/s2665-9913(23)00066-8', 'ISSN': ['2665-9913'], 'URL': 'http://dx.doi.org/10.1016/S2665-9913(23)00066-8', 'alternative-id': ['S2665991323000668'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the ' 'COVID-19 Vaccination in Autoimmune Diseases (COVAD) study'}, {'label': 'Journal Title', 'name': 'journaltitle', 'value': 'The Lancet Rheumatology'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': 'https://doi.org/10.1016/S2665-9913(23)00066-8'}, {'label': 'Content Type', 'name': 'content_type', 'value': 'simple-article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2023 Elsevier Ltd. All rights reserved.'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1630-6026', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Sen', 'given': 'Parikshit', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0003-2014-3925', 'affiliation': [], 'authenticated-orcid': False, 'family': 'R', 'given': 'Naveen', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-3849-614X', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Nune', 'given': 'Arvind', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-8528-4361', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Day', 'given': 'Jessica', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-7312-351X', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Joshi', 'given': 'Mrudula', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-4508-1233', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Agarwal', 'given': 'Vikas', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-7531-8038', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Aggarwal', 'given': 'Rohit', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-2753-2990', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Gupta', 'given': 'Latika', 'sequence': 'additional'}], 'container-title': 'The Lancet Rheumatology', 'container-title-short': 'The Lancet Rheumatology', 'content-domain': { 'crossmark-restriction': True, 'domain': ['thelancet.com', 'elsevier.com', 'sciencedirect.com']}, 'created': {'date-parts': [[2023, 4, 24]], 'date-time': '2023-04-24T22:29:13Z', 'timestamp': 1682375353000}, 'deposited': { 'date-parts': [[2023, 4, 25]], 'date-time': '2023-04-25T00:32:28Z', 'timestamp': 1682382748000}, 'indexed': {'date-parts': [[2023, 4, 25]], 'date-time': '2023-04-25T04:35:19Z', 'timestamp': 1682397319017}, 'is-referenced-by-count': 0, 'issue': '5', 'issued': {'date-parts': [[2023, 5]]}, 'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2023, 5]]}}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 5, 1]], 'date-time': '2023-05-01T00:00:00Z', 'timestamp': 1682899200000}}, { 'URL': 'https://doi.org/10.15223/policy-017', 'content-version': 'stm-asf', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 5, 1]], 'date-time': '2023-05-01T00:00:00Z', 'timestamp': 1682899200000}}, { 'URL': 'https://doi.org/10.15223/policy-037', 'content-version': 'stm-asf', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 5, 1]], 'date-time': '2023-05-01T00:00:00Z', 'timestamp': 1682899200000}}, { 'URL': 'https://doi.org/10.15223/policy-012', 'content-version': 'stm-asf', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 5, 1]], 'date-time': '2023-05-01T00:00:00Z', 'timestamp': 1682899200000}}, { 'URL': 'https://doi.org/10.15223/policy-029', 'content-version': 'stm-asf', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 5, 1]], 'date-time': '2023-05-01T00:00:00Z', 'timestamp': 1682899200000}}, { 'URL': 'https://doi.org/10.15223/policy-004', 'content-version': 'stm-asf', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 5, 1]], 'date-time': '2023-05-01T00:00:00Z', 'timestamp': 1682899200000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2665991323000668?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2665991323000668?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': 'e247-e250', 'prefix': '10.1016', 'published': {'date-parts': [[2023, 5]]}, 'published-print': {'date-parts': [[2023, 5]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'DOI': '10.1016/S1473-3099(21)00703-9', 'article-title': 'A clinical case definition of post-COVID-19 condition by a Delphi ' 'consensus', 'author': 'Soriano', 'doi-asserted-by': 'crossref', 'first-page': 'e102', 'journal-title': 'Lancet Infect Dis', 'key': '10.1016/S2665-9913(23)00066-8_bib1', 'volume': '22', 'year': '2022'}, { 'DOI': '10.1136/annrheumdis-2020-219498', 'article-title': 'Factors associated with COVID-19-related death in people with rheumatic ' 'diseases: results from the COVID-19 Global Rheumatology Alliance ' 'physician-reported registry', 'author': 'Strangfeld', 'doi-asserted-by': 'crossref', 'first-page': '930', 'journal-title': 'Ann Rheum Dis', 'key': '10.1016/S2665-9913(23)00066-8_bib2', 'volume': '80', 'year': '2021'}, { 'DOI': '10.1016/j.semarthrit.2022.152025', 'article-title': 'DMARD disruption, rheumatic disease flare, and prolonged COVID-19 ' 'symptom duration after acute COVID-19 among patients with rheumatic ' 'disease: a prospective study', 'author': 'Di Iorio', 'doi-asserted-by': 'crossref', 'journal-title': 'Semin Arthritis Rheum', 'key': '10.1016/S2665-9913(23)00066-8_bib3', 'volume': '55', 'year': '2022'}, { 'DOI': '10.1007/s00296-022-05157-6', 'article-title': 'COVAD survey 2 long-term outcomes: unmet need and protocol', 'author': 'Fazal', 'doi-asserted-by': 'crossref', 'first-page': '2151', 'journal-title': 'Rheumatol Int', 'key': '10.1016/S2665-9913(23)00066-8_bib4', 'volume': '42', 'year': '2022'}, { 'DOI': '10.1136/rmdopen-2022-002587', 'article-title': 'Prolonged COVID-19 symptom duration in people with systemic autoimmune ' 'rheumatic diseases: results from the COVID-19 Global Rheumatology ' 'Alliance Vaccine Survey', 'author': 'DiIorio', 'doi-asserted-by': 'crossref', 'journal-title': 'RMD Open', 'key': '10.1016/S2665-9913(23)00066-8_bib6', 'volume': '8', 'year': '2022'}, { 'DOI': '10.1007/s11606-022-07997-1', 'article-title': 'Racial/ethnic disparities in the incidence of post-acute sequelae of ' 'SARS-CoV-2 infection in New York: an EHR-based cohort study from the ' 'RECOVER program', 'author': 'Khullar', 'doi-asserted-by': 'crossref', 'journal-title': 'J Gen Intern Med', 'key': '10.1016/S2665-9913(23)00066-8_bib7', 'year': '2023'}, { 'DOI': '10.1038/s41591-022-01909-w', 'article-title': 'Symptoms and risk factors for long COVID in non-hospitalized adults', 'author': 'Subramanian', 'doi-asserted-by': 'crossref', 'first-page': '1706', 'journal-title': 'Nat Med', 'key': '10.1016/S2665-9913(23)00066-8_bib8', 'volume': '28', 'year': '2022'}, { 'DOI': '10.4997/jrcpe.2021.405', 'article-title': 'Incidence and risk factors of long COVID in the UK: a single-centre ' 'observational study', 'author': 'Nune', 'doi-asserted-by': 'crossref', 'first-page': '338', 'journal-title': 'J R Coll Physicians Edinb', 'key': '10.1016/S2665-9913(23)00066-8_bib9', 'volume': '51', 'year': '2021'}, { 'DOI': '10.1016/S0140-6736(20)32656-8', 'article-title': '6-month consequences of COVID-19 in patients discharged from hospital: ' 'a cohort study', 'author': 'Huang', 'doi-asserted-by': 'crossref', 'first-page': '220', 'journal-title': 'Lancet', 'key': '10.1016/S2665-9913(23)00066-8_bib10', 'volume': '397', 'year': '2021'}], 'reference-count': 9, 'references-count': 9, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2665991323000668'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Immunology', 'Immunology and Allergy', 'Rheumatology'], 'subtitle': [], 'title': 'Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination ' 'in Autoimmune Diseases (COVAD) study', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'volume': '5'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit